News & Updates
Filter by Specialty:
First-line durvalumab plus tremelimumab safe to use in unresectable HCC
The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.
First-line durvalumab plus tremelimumab safe to use in unresectable HCC
05 Sep 2025
Supplemental imaging strategies facilitate early cancer detection in women with dense breasts
Supplemental breast cancer (BC) imaging techniques may help detect early cancers that standard mammograms may have missed in women with dense breasts, according to interim results from the BRAID* trial.
Supplemental imaging strategies facilitate early cancer detection in women with dense breasts
05 Sep 2025
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
Patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma demonstrate significant improvements in event-free survival (EFS) following treatment with durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy compared with placebo plus FLOT, as shown by the results of the phase III MATTERHORN study.
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
04 Sep 2025
Quitting smoking may help recovery from substance use disorders
Smoking cessation is associated with sustained recovery from substance use disorders (SUDs), according to a longitudinal cohort study funded by the US National Institutes of Health (NIH).